Datasets
Buyer room
KITSA.AIManage supplier listing
Kitsa (Trial Watch clinical trial intelligence) — Editorially triaged clinical-trial event stream: every ~14 days the full new-registration universe is screened and a fixed slate of 15 'high-signal' trials is selected and written up with sponsor, phase, population/age bracket, modality class, indication, comparator and trial size. The licensable asset is the selection/triage layer plus per-trial structured attributes and first-in-class flags (e.g. largest mRNA-vaccine efficacy trial ever registered, first in vivo CD19 CAR-T, first clinical prime-editing trial), not the registry records themse…
supplier index read from their site
Editorially triaged clinical-trial event stream: every ~14 days the full new-registration universe is screened and a fixed slate of 15 'high-signal' trials is selected and written up with sponsor, phase, population/age bracket, modality class, indication, comparator and trial size. The licensable asset is the selection/triage layer plus per-trial structured attributes and first-in-class flags (e.g. largest mRNA-vaccine efficacy trial ever registered, first in vivo CD19 CAR-T, first clinical prime-editing trial), not the registry records themselves.
Coverage Health Care · Information TechnologyAsset class EquitiesTickers GSK · LLY · AZN
Sample, licence terms, pricing and eval results when Kitsa publishes them. Until then, discover alternatives today with a 7-day trial.
Start 7-day trial →What buyers ask about Kitsa, answered from this page.
Kitsa (Trial Watch clinical trial intelligence) — Editorially triaged clinical-trial event stream: every ~14 days the full new-registration universe is screened and a fixed slate of 15 'high-signal' trials is selected and written up with sponsor, phase, population/age bracket, modality class, indication, comparator and trial size. The licensable asset is the selection/triage layer plus per-trial structured attributes and first-in-class flags (e.g. largest mRNA-vaccine efficacy trial ever registered, first in vivo CD19 CAR-T, first clinical prime-editing trial), not the registry records themse…
Kitsa offers (Alternative, Fundamental, Sentiment) — ~255 curated trial write-ups to date (17 editions x 15 trials) with per-trial structured attributes and editorial rationale, produced against a screening universe of the full public registry (~550K+ registered studies screened each fortnight); ~26 editions per year at the current cadence.
Supervised training/evaluation data for trial-relevance ranking models (a human-curated 'what matters this fortnight' ground set against the raw registration firehose); biotech and pharma competitive-intelligence and pipeline-share tracking by therapeutic area and modality; modality-adoption and timing studies (when in vivo CAR-T or prime editing crossed into pivotal); event-driven equity research using large pivotal starts as catalysts; licensing and business-development landscape scanning; pharma commercial and medical-affairs market sizing from enrolment trajectories
Coverage spans US, UK, China/HK; Health Care Technology, Application Software; alternative, fundamental, sentiment; equities.
Kitsa has not added their own details yet. Not yet on file: